Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Prostate Cancer

July 31, 2020

Optimizing Care and Managing Side Effects in Prostate Cancer
Clinicians need up-to-date information on when and how to use molecular assays to inform individual patient risk, so that men with localized prostate cancer can receive optimal treatment while avoiding unnecessary treatment and side effects. In addition, clinicians must be knowledgeable about the side effects of androgen deprivation therapy (ADT) and management options for these side effects. Finally, clinicians must be aware of results of recent clinical trials in the non-metastatic castration-resistant prostate cancer (CRPC) setting, so that patients can receive optimal care and delay the onset of metastases as long as possible.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Identify patients with localized prostate cancer for whom molecular profiling may inform treatment decisions. 
  • Recognize and manage the side effects of androgen deprivation therapy (ADT). 
  • Apply the results of recent clinical trials in the non-metastatic castration-resistant prostate cancer (CRPC) setting to optimize patient care.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Clovis Oncology, Inc.
  • Daiichi Sankyo, Inc.
  • GlaxoSmithKline
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Lilly
  • Novartis
  • Puma Biotechnology
  • Seattle Genetics, Inc.
  • Taiho Oncology, Inc.

This activity is supported by independent educational grants from:

  • Astellas and Pfizer, Inc.
  • Merck  & Co., Inc.

This activity is supported by independent medical education grants from:

  • Bristol Myers Squibb
  • Sanofi Genzyme

This educational activity is supported by medical education grants from:

  • Exelixis, Inc.
  • Karyopharm Therapeutics
Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
05/26/2020
Course expires: 
10/02/2020
Event starts: 
07/31/2020 - 1:30pm
Event ends: 
07/31/2020 - 2:30pm
Cost:
$0.00

Edward Schaeffer, MD, PhD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Alicia K. Morgans, MD, MPH
Northwestern University Feinberg School of Medicine

 

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions  
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures
The faculty listed below discloses the following relevant financial relationships:
Alicia K. Morgans, MD, MPH
Advanced Accelerator Applications: Consulting Fee 
Astellas Pharma US, Inc.: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee
Bayer HealthCare: Consulting Fee; Grant/Research Support
Janssen Pharmaceutica Products, LP: Consulting Fee
Myovant Sciences Ltd.: Consulting Fee
sanofi-aventis U.S.: Consulting Fee

Edward Schaeffer, MD, PhD
AbbVie, Inc.: Scientific Advisor
Janssen Scientific Affairs, LLC: Scientific Advisor

NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein

The NCCN Clinical staff listed below discloses no relevant financial relationships:
Deborah Freedman-Cass, PhD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-20-073-L01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 0.75 CE contact hour. Activity Code: I00042797; Approval #: 200137711

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

This webinar was presented live one time only on Friday, July 31, 2020, from 1:30 - 2:30 PM EDT (UTC -4).

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing